IL13RA2 and diffuse large B-cell lymphoma: CAR-T cells have received FDA approval in diffuse large B cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).214,215 The most studied targets of CAR-T in GBM are HER2, EGFRvIII, as well as IL-13αR2, which have already been published in clinical trial results.216–220 O’Rourke, et al stated that EGFRvIII-directed CAR-T cells are effective and safe.106 Brown, et al used CAR-T cells targeting IL-13Rα2 in recurrent GBM patients.